Executive Vice President and Chief Operating Officer · TANDEM DIABETES CARE INC (TNDM)

Jean-Claude Kyrillos

FY2024 is the first fiscal year CompBrief holds for Jean-Claude Kyrillos as a named executive officer of TANDEM DIABETES CARE; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,431,600

Salary $239,286Stock awards $2,063,888

3rd of 6 named executive officers at Tandem Diabetes Care by FY2024 total.

6 named officers on file for TANDEM DIABETES CARE, FY2024

Jean-Claude Kyrillos’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • TNDM’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how TANDEM DIABETES CARE’s whole pay program stands against its peers

  • TANDEM DIABETES CARE’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TNDM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 8, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Jean-Claude Kyrillos’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Jean-Claude Kyrillos compensation by year

TANDEM DIABETES CARE Summary Compensation Table · the one fiscal year held
In US dollars, as TANDEM DIABETES CARE reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$239,286
Bonus$0
Stock awards$2,063,888
Option awards$0
Non-equity incentive$121,810
Pension and deferred compensation$0
All other$6,616
Total$2,431,600

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TANDEM DIABETES CARE INC DEF 14A filed April 8, 2025, accession 0001438133-25-000058, and prior-year filings. Open the filing on EDGAR.

How this page was built: the TANDEM DIABETES CARE INC filed document, accession 0001438133-25-000058. Every figure is read from that document and cited to the page and table it appears in. Filed April 8, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU43,634$1,571,697—

Per the Outstanding Equity Awards at Fiscal Year-End table in TANDEM DIABETES CARE INC's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

34 Form 4 lines since the FY2024 proxy (filed April 8, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-16Grant or award—207$11.5132,682
2026-11-15Exercise or conversion derivative—1,009$0.006,058
2026-11-15Exercise or conversion—1,009$0.0033,010
2026-11-15Tax withholding—535$20.0732,475
2026-10-15Tax withholding—1,926$16.5232,001
2026-10-15Exercise or conversion—3,637$0.0033,927
2026-10-15Exercise or conversion derivative—3,637$0.0010,908
2026-08-15Exercise or conversion derivative—1,010$0.007,067

The 8 most recent of 34 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Change-in-control & termination

estimated payments TANDEM DIABETES CARE discloses, by trigger · FY2024
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Change in control and involuntary termination$1,080,487$1,571,697—$2,652,184
Change in control and resignation for good reason$1,080,487$1,571,697—$2,652,184

Per the Potential Payments Upon Termination or Change in Control table in TANDEM DIABETES CARE INC's FY2024 proxy. Estimates as the company printed them; a dash means it printed no figure.

TANDEM DIABETES CARE’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
John SheridanPresident and Chief Executive Officer$8,526,238
Leigh VossellerExecutive Vice President, Chief Financial Officer and Treasurer$2,480,081
Jean-Claude Kyrillos · this pageExecutive Vice President and Chief Operating Officer$2,431,600
Susan MorrisonExecutive Vice President and Chief Administrative Officer$2,005,471
Elizabeth GasserExecutive Vice President and Chief Strategy and Product Officer$2,005,471
Mark NovaraExecutive Vice President and Chief Commercial Officer$802,745

The full TANDEM DIABETES CARE compensation record

free company brief

This page is one person within TANDEM DIABETES CARE's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the TANDEM DIABETES CARE proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TANDEM DIABETES CARE's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jean-Claude Kyrillos's compensation dossier · One-time report. No refunds.